Abstract
Background Kidney transplantation is the preferred treatment for end-stage renal disease, but delayed graft function remains a significant complication. Cold ischemia during organ preservation can lead to the release of danger-associated molecular patterns (DAMPs), which may influence graft outcomes. This study aimed to quantify DAMPs in kidney preservation fluid and assess their correlation with delayed graft function (DGF).
Methods Preservation fluid samples from 88 deceased kidney donors were analyzed for various DAMPs, including mitochondrial DNA (mitDNA), cytochrome c, nucleosomes, hyaluronan, and inflammasome-related molecules (IL-18 and IL-1β). The influence of donor type (DBD vs. DCD) and cold ischemia time (CIT) on DAMP concentrations was evaluated. Additionally, the correlation between DAMP levels and DGF was assessed.
Results Multiple DAMPs were detected in preservation fluid, including mitDNA, cytochrome c, nucleosomes, and hyaluronan. The type of donation (DBD vs. DCD) had minimal impact on DAMP concentrations, except for HSP70, which was significantly higher in DCD donors. CIT positively correlated with hyaluronan and nucleosome levels. Cytochrome c emerged as a potential biomarker for DGF, showing a significant increase in patients with early dysfunction and correlating with post-transplant creatinine levels.
Conclusions Quantifying DAMPs in kidney preservation fluid is feasible and may provide valuable insights into graft quality and early post-transplant outcomes. Cytochrome c, in particular, shows promise as a biomarker for predicting delayed graft dysfunction. These findings highlight the importance of minimizing cold ischemia time and suggest that DAMP analysis could improve graft assessment prior to transplantation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Instituto de Salud Carlos III (DTS23/00013) and Fundacion Seneca de la Region de Murcia (22257/PDC/23)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Hospital Clinico Universitario Virgen de la Arrixaca gave ethical approval for this work (2023-1-2-HCUVA)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Ethics committee/IRB of Full Institution name gave ethical approval for this work
